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Background: Multimorbidity, defined as the co-occurrence of ≥2 chronic conditions, is
clinically diverse. Such complexity hinders the development of integrated/collaborative
care for multimorbid patients. In addition, the universality of multimorbidity patterns is
unclear given scarce research comparing multimorbidity profiles across populations. This
study aims to derive and compare multimorbidity profiles in Hong Kong (HK, PRC) and
Zurich (ZH, Switzerland).
Methods: Stratified by sites, hierarchical agglomerative clustering analysis (dissimilarity
measured by Jaccard index) was conducted with the objective of grouping inpatients
into clinically meaningful clusters based on age, sex, and 30 chronic conditions among
20,000 randomly selected discharged multimorbid inpatients (10,000 from each site)
aged ≥ 45 years. The elbow point method based on average within-cluster dissimilarity,
complemented with a qualitative clinical examination of disease prevalence, was used to
determine the number of clusters.
Results: Nine clusters were derived for each site. Both similarities and dissimilarities of
multimorbidity patterns were observed. There was one stroke-oriented cluster (3.9% in
HK; 6.5% in ZH) and one chronic kidney disease-oriented cluster (13.1% in HK; 11.5%
ZH) in each site. Examples of site-specific multimorbidity patterns, on the other hand,
included a myocardial infarction-oriented cluster in ZH (2.3%) and several clusters in HK
with high prevalence of heart failure (>65%) and chronic pain (>20%).
Conclusion: This is the first study using hierarchical agglomerative clustering analysis
to profile multimorbid inpatients from two different populations to identify universalities
and differences of multimorbidity patterns. Our findings may inform the coordination of
integrated/collaborative healthcare services.
Keywords: comorbidity, machine learning, multiple chronic conditions, non-communicable disease, population
aging
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INTRODUCTION
Multimorbidity is commonly referred to as the co-occurrence of
two or more chronic health conditions (1) and is consistently
associated with poorer quality of life (2), more healthcare
utilization (3), deteriorating mental health (4), and greater risk
of mortality (5). Various models of care have been proposed and
trialed to address this complexity in clinical practices (6, 7).
Multimorbid patients are clinically diverse (8) and may
have markedly different prognoses due to different disease
combinations (9). Such heterogeneity limits the provision of
integrated or collaborative care in various healthcare settings
(10, 11) as evidence-based clinical guidelines are inadequate (12)
given the scarcity of randomized controlled trials conducted on
multimorbid populations (13), even those with more prevalent
disease combinations (14). This challenge is often further
complicated by the need to manage multiple drug regimens
(polypharmacy) (15) and the associated adverse effects (16).
Numerous attempts have thus been made to identify common
patterns of multimorbidity to simplify the problem (8, 17).
Prados-Torres et al. (17) identified 97 different combinations
of two or more co-occurring chronic conditions, which were
mostly represented as cardiometabolic, musculoskeletal, and
mental patterns. In a more recent review, Ng et al. (8) updated
the literature search and evaluated the methods by which
multimorbidity patterns are identified. Clustering analysis has
been found to be the commonest approach to identifying
disease patterns: grouping together similar diseases that are
found in the same individuals (8, 17). While this approach
omits the possibility that one disease may belong with more
than one cluster and that even individuals with the same
disease may be clinically distinct from each other given other
conditions, very few reviewed studies (18) adopted clustering
analysis or other methods to group similar patients instead of
similar diseases (8, 17). Furthermore, very few studies have
compared multimorbidity patterns across countries using the
same methods (19). Similarities and dissimilarities between
multimorbidity patterns observed in different contexts, therefore,
remain unexplored. In fact, the presence of universal patterns
may strengthen the rationale for more randomized controlled
trials to be conducted on multimorbid patients because results
would confer cross-country implications.
This study aims to describe and compare the patterns of co-
occurring chronic conditions among discharged multimorbid
inpatients in Hong Kong and Zurich using a hierarchical
agglomerative clustering analytic approach, which is typically
used for grouping similar individuals based on predetermined
ranges of characteristics. Since the healthcare system as well as
the cultural and demographic characteristics differ drastically
between the two sites, observations of similar multimorbidity
patterns may potentially imply universal challenges facing
clinicians globally.
MATERIALS AND METHODS
Study Design and Data Collection
We conducted a retrospective analysis of clinical records of
discharged patients aged ≥ 45 from all public hospitals in
Hong Kong (representing >90% of all inpatient services) during
January 2010-December 2013 and from the University Hospital
Zurich (general acute hospital, teaching hospital for University
of Zurich) during August 2009-August 2017. The discrepancy of
observation period was mainly due to the much smaller amount
of data generated from Zurich as it is only one hospital compared
with the whole public hospital system in Hong Kong.
The data contained information on patients’ age, sex, the
length of stay, and the first 15 clinical diagnoses made during
the hospital stay coded with the International Classification of
Diseases, Ninth Revision (ICD-9) for Hong Kong and with
the Tenth Revision (ICD-10) for Zurich. Multimorbidity is
defined as having two or more chronic conditions using a
list of 30 diseases coded either by ICD-9 or ICD-10. The list
of chronic conditions is based on validated coding algorithms
summarized by Tonelli et al. (20) and included alcohol misuse,
asthma, atrial fibrillation, chronic heart failure, chronic kidney
disease, chronic pain, chronic pulmonary disease, chronic viral
hepatitis B, cirrhosis, dementia, depression, diabetes, epilepsy,
hypertension, hypothyroidism, inflammatory bowel disease,
irritable bowel syndrome, lymphoma, metastatic cancer, multiple
sclerosis, myocardial infarction, non-metastatic cancer (breast,
cervical, colorectal, lung, and prostate), Parkinson’s disease,
peptic ulcer disease, peripheral vascular disease, psoriasis,
rheumatoid arthritis, schizophrenia, severe constipation, and
stroke or transient ischemic attack (TIA). These diseases are
all convertible between ICD-9 and ICD-10 in accordance with
the Tonelli algorithms and therefore diseases could be mapped
between the sites. Ten thousand patients with two or more of
these conditions from each site were randomly selected and
included with the “sample” function according to approach
described by Ripley (21) in R, version 3.6.0 (R Foundation
for Statistical Computing, Vienna, Austria). This sample size
was approximately four times the minimum required number
recommended for a clustering analysis of 32 variables (22).
30-day readmission and length of stay in hospital were
measured to compare health care utilizations between clusters
and sites. We considered only the first discharge of each patient
during the data collection period to observe their clinical profiles
and length of stay, then followed them up 30 days after their
baseline discharge to observe any readmission.
Clustering Analysis
Stratified by sites (Hong Kong and Zurich), a hierarchical
agglomerative clustering analysis implemented with R package
“hclust” was conducted to form clusters of patients starting by
grouping similar individuals in terms of age groups (categorized
according to the World Health Organization’s 5-year intervals:
45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80+), sex, and the
presence of listed chronic conditions with dissimilarity between
patients measured by Jaccard index (23). Using the Ward’s
method, the pair of clusters or patients merged in each step was
the one associated with the smallest increase in the total within-
cluster dissimilarity. To inform our decision on the number of
clusters to be specified, we first plotted the total within-cluster
dissimilarity by number of specified clusters to look for an elbow
point at which total within-cluster dissimilarity cease to decrease
significantly, then we conducted a qualitative examination of
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the disease prevalence across clusters to eventually determine
the optimal number of clusters from a clinical perspective, i.e.,
the balance between interpretability and meaningful clinical
grouping of patients. Clustering of patients was then compared
between sites.
We performed statistical analyses with R and there were no
missing data in the anonymized hospital records. An ethics
waiver has been granted by Cantonal Ethics Committee of Zurich
for the analysis of Zurich inpatient data (Ref: NZ-B-Nr.2017-
00882) while the analysis of Hong Kong inpatient data was
approved by the Survey and Behavioral Ethics Committee of the
Chinese University of Hong Kong (Project Code: Elderly Care
– CUHK). As only secondary analysis of anonymized inpatient
data was performed, no informed consent was required.
RESULTS
Over the corresponding study periods (see Figure 1), there were
1,015,225 inpatients aged ≥ 45 discharged from Hong Kong
public hospitals among which 144,711 were multimorbid; and
of the 102,936 discharged from the University Hospital Zurich,
37,574 were multimorbid. For each site, 10,000 patients were
randomly selected for analysis.
Comparison of Disease Prevalence and
Demographics
Table 1 shows the comparison of sample characteristics and
disease prevalence between sites. First, the sample from Hong
Kong had an older median age (75 vs. 70) and fewer males
(51.2 vs. 57.6%) than the Zurich sample. Second, while 30-
day readmission rate was similar, the median length of current
stay is substantially greater in Zurich (7 vs. 4 days). Third,
patients from Zurich had more diagnoses than those from Hong
Kong, where only 1.4% of the sample had five or more diseases,
compared with 5.0% in Zurich. There were notable differences
in specific disease prevalence between the sites. Prevalence of
alcohol misuse, epilepsy, and cancer prevalence among patients
in Zurich was about triple that in Hong Kong. Much fewer
Zurich patients had atrial fibrillation and heart failure compared
with Hong Kong patients and there was a sharp contrast in
peripheral vascular disease prevalence (0.0% in Hong Kong vs.
10.4% in Zurich).
Comparison of Disease Dyads
Figure 2 shows two chord diagrams which represent the
frequencies of each disease dyad in both sites (represented by
ribbon width). There were 54,052 co-occurring pairs of diseases
FIGURE 1 | Graphical representation of the sample selection for the analysis.
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TABLE 1 | Comparison of demographics and disease prevalence between sites.
Hong Kong Zurich
N 10,000 10,000 P-valuea
Age (median [IQR]) 75 [64, 82] 70 [61, 78] <0.001
Male (%) 5,125 (51.2) 5756 (57.6) <0.001
Length of current stay (median [IQR]) 4 [2, 9] 7 [3, 13] <0.001
30-day readmission (%) 1,034 (10.3) 1,185 (11.8) 0.001
Number of chronic diseases (%) <0.001
Two 6,727 (67.3) 5,461 (54.6)
Three 2,503 (25.0) 2,865 (28.6)
Four 635 (6.3) 1,171 (11.7)
Five or more 135 (1.4) 503 (5.0)
Chronic diseases (%)
Alcohol misuse 176 (1.8) 650 (6.5) <0.001
Asthma 314 (3.1) 220 (2.2) <0.001
Atrial fibrillation 1,531 (15.3) 654 (6.5) <0.001
Cancer, lymphoma 26 (0.3) 195 (1.9) <0.001
Cancer, metastatic 200 (2.0) 768 (7.7) <0.001
Cancer, non-metastatic 285 (2.8) 481 (4.8) <0.001
Chronic kidney disease 1,499 (15.0) 1,721 (17.2) <0.001
Chronic pain 1,614 (16.1) 2,764 (27.6) <0.001
Chronic pulmonary disease 752 (7.5) 827 (8.3) 0.052
Cirrhosis 932 (9.3) 1,019 (10.2) 0.04
Dementia 237 (2.4) 44 (0.4) <0.001
Depression 211 (2.1) 172 (1.7) 0.05
Diabetes 354 (3.5) 409 (4.1) 0.046
Epilepsy 307 (3.1) 943 (9.4) <0.001
Heart failure 4,945 (49.5) 2,925 (29.2) <0.001
Hepatitis B 166 (1.7) 496 (5.0) <0.001
Hypertension 7,132 (71.3) 7,438 (74.4) <0.001
Hypothyroidism 235 (2.4) 916 (9.2) <0.001
Inflammatory bowel disease 8 (0.1) 72 (0.7) <0.001
Irritable bowel syndrome 11 (0.1) 15 (0.1) 0.556
Multiple sclerosis 14 (0.1) 49 (0.5) <0.001
Myocardial infarction 407 (4.1) 894 (8.9) <0.001
Parkinson’s disease 243 (2.4) 164 (1.6) <0.001
Peptic Ulcer Disease 195 (1.9) 57 (0.6) <0.001
Peripheral Vascular Disease 3 (0.0) 1,044 (10.4) <0.001
Psoriasis 26 (0.3) 65 (0.6) <0.001
Rheumatoid arthritis 177 (1.8) 346 (3.5) <0.001
Schizophrenia 171 (1.7) 93 (0.9) <0.001
Severe constipation 447 (4.5) 182 (1.8) <0.001
Stroke 1,577 (15.8) 1,265 (12.6) <0.001
aP-value indicates the statistical significance of chi-square test (or Fisher’s exact test for
frequencies smaller than five) comparing socio-demographics and disease prevalence
between sites.
in the Zurich sample but only 38,964 in the Hong Kong sample,
plausibly due to the fact that patients in Zurich had more
diagnoses (see Table 1). In general, the patterns of disease dyads
were fairly similar. Among all dyads in Hong Kong, 10,701
were related to hypertension, 7,815 to heart failure, and 2,967
to chronic pain. In Zurich, 13,294 were related to hypertension,
6,252 to chronic pain, and 6,166 to heart failure. Patients in
Zurich hadmore differentmultimorbidity patterns (more narrow
ribbons): based on the presence and absence of the 30 listed
diseases, there were 1,799 configurations among patients in
Zurich but only 982 in Hong Kong.
Comparison of Clusters Between Sites
Figure 3 shows the average within-cluster dissimilarity by
number of specified clusters. Based on the elbow point method, at
five clusters, within-cluster dissimilarity ceased to decline further
significantly. Hence, we examined clustering schemes from 5 to
10 specified clusters in each site. This clinical review of clustering
schemes indicated that at nine clusters, a balance between
interpretability and meaningful categorization of patients was
achieved. Thus, clustering patterns with nine specified clusters
are presented. The order of clusters was in accordance with the
size of the clusters (#1 being largest and #9 smallest).
Figures 4, 5 show the characterizing diseases by clusters (most
prevalent diseases within clusters and diseases that were most
prevalent compared with other clusters) in each site respectively,
while Tables 2, 3 show exact disease prevalence, median age,
median length of stay, and 30-day readmission rates of clusters.
Accordingly, each site had one stroke-oriented cluster (>90%
prevalence), one among older adults in Hong Kong (Hong
Kong: H9, see Table 2) and another among males in Zurich
(Zurich: cluster Z8, see Table 3). In both clusters, hypertension
and heart failure were relatively prevalent. Figure 6 shows a
comparison of the chord diagrams of these two clusters (H9 and
Z8) representing all disease dyads in each site. Further, there was
one chronic kidney disease-oriented cluster (>50% prevalence)
in each site (H3 and Z3) and both clusters also featured atrial
fibrillation (see Figure 7 for chord diagram comparison). While
53% of patients in Z3 suffered from chronic pain, H3 showed
the highest prevalence of myocardial infarction across clusters
in Hong Kong. The only myocardial infarction-oriented cluster
in the study was generated for Zurich among relatively young
males (Z9). Zurich featured two additional unique clusters, i.e.,
epilepsy sometimes combined with chronic pulmonary disease
in young patients (Z7), and hypothyroidism in older females
(Z5). Several clusters in Hong Kong featured high heart failure
prevalence (H2, H6, H8, H4), and chronic pain was also relatively
prevalent in those clusters. Two clusters in Zurich (Z6, Z2)
showed heart failure prevalence over 50%, but only Z6 had a
high proportion of chronic pain. Z2 on the other hand featured
the highest prevalence of peripheral vascular disease across all
clusters, whereas that diagnosis was rare in Hong Kong. Some
clusters in Hong Kong and Zurich had mixed features and were
thus less clear, including chronic pulmonary disease with stroke
and heart failure (H5), cirrhosis with severe constipation (H1),
depression, dementia, and alcohol misuse (H7), chronic pain and
diabetes (Z1), as well as metastatic cancer, cirrhosis, and hepatitis
B (Z4).
DISCUSSION
Findings of this study provide an overview of the clustering
patterns of multimorbidity based on which further investigations
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FIGURE 2 | Chord diagrams showing the frequencies of disease dyads among inpatients from Hong Kong (38,964 disease dyads) and Zurich (54,052 disease dyads).
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FIGURE 3 | Within-cluster dissimilarity index (measured by Jaccard Index) by
number of clusters derived from hierarchical agglomerative clustering and by
jurisdictions, i.e., Hong Kong and Zurich.
could be conducted to inform potential integration of services
and collaboration between medical specialties. In addition, the
comparison between patient records from Hong Kong and
Zurich provide preliminary results on the degree of universality
of multimorbidity patterns across world populations. Overall
speaking, there were no striking similarities or dissimilarities
of the identified clustering patterns beyond established disease
relationships between the two sites, with the co-occurrence
of known comorbidities being most frequently observed.
Specifically, only two out of nine clusters were found to be
common clusters across the two sites. In both sites, especially
in Hong Kong where fewer diagnoses were recorded, disease
dyads mostly fell within the same medical specialties, which
may suggest the importance of integrated practices within the
specialty relative to cross-specialty collaboration.
Interpretation and Implications
While a focused examination of disease prevalence within each
cluster reflect only the previously identified disease relationships,
the overall findings jointly represent the distribution ofmorbidity
burden within and across clusters among multimorbid patients
in a realistic healthcare setting. In other words, an overall
clinical profile of multimorbid inpatients in terms of a variety
of chronic conditions is presented. While the differences
between the sites may be attributed to the different healthcare
delivery and financing mechanisms as well as cultural and
demographic factors, the identified similarities of multimorbidity
patterns may suggest common specific segments of patients
requiring further attention across populations, and the results
convey important information on the management level for
the planning and coordination of services for multimorbid
patients in hospitals and other healthcare facilities. For instance,
although it is commonly known that chronic kidney disease
and atrial fibrillation are closely related diseases (24), our
analysis further showed that patients having these two conditions
constituted a significant proportion of multimorbid patients in
both sites. Hence, the successful implementation of integrated
care for these patients may alleviate the healthcare burden of
multimorbidity significantly.
Likewise, the presence of stroke-oriented clusters which
have been observed in both sites, despite having different
demographics, suggest that stroke and associated morbidities
(25, 26) represent a sizeable proportion of multimorbid patients
in a hospital setting. While there are existing integrated services
for stroke patients in typical healthcare systems of developed
societies, it is also important to assess the degree to which these
patients contribute to the total burden of multimorbidity.
There are also unique clusters in each site which may be of
clinical importance. Specifically, only in Zurich did we observe
a myocardial infarction-oriented cluster (99% prevalence). Also,
the prevalence of peripheral vascular disease is drastically
higher in the sample of Zurich than that of Hong Kong.
These results may suggest potentially different etiologies of
cardiovascular diseases between Hong Kong and Zurich due to
different lifestyles, living environments, and economic structures.
Nevertheless, such difference may also be attributed to different
specialization foci of the hospitals, different referral patterns, and
other practices that may differ between sites. More observations
are needed to investigate the underlying reasons.
In Hong Kong, the clusters featuring high prevalence (>65%)
of heart failure also had relatively high prevalence of chronic
pain, which was partially the case in Zurich. This may relate to the
regular practice of hospital clinicians in the assessment of heart
failure which include the report of pain (27, 28). If confirmed
by further research, this begs the question whether chronic pain
prevalence is currently being underestimated among patients
with other diseases (without assessment of pain) and, hence,
whether it is necessary to include the assessment of pain
for them. In fact, the observed prevalence of heart failure is
apparently higher compared with previous inpatient research in
other populations, such as in Canada (29). Further research is
recommended to examine the potentially underlying reasons for
this difference.
In each of the two sites, there existed highly complex clusters
(H7 and Z4) in which a wide variety of diseases was featured.
However, as these clusters did not constitute a markedly large
proportion of multimorbid patients, integrated or collaborative
care for the rest of the clusters with obvious characterizing
diseases should be the priority for alleviating the healthcare
burden of multimorbidity.
Relationship With the Literature
While the results of this study are context specific, it provides
preliminary information on the replicability of multimorbidity
profiling between populations. In the literature, there are at
least two recent important systematic reviews on the results of
multimorbidity profiling from previous research with a huge
variety of statistical methods (8, 30). It has been suggested that
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FIGURE 4 | Clustering process (from seven to nine clusters) of Hong Kong inpatients labeled with characterizing diseases.
FIGURE 5 | Clustering process (from seven to nine clusters) of Zurich inpatients labeled with characterizing diseases.
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TABLE 2 | Prevalence of chronic conditions by cluster (Hong Kong)*.
Cluster H1 H2 H3 H4 H5 H6 H7 H8 H9
N 1,869 1,837 1,306 1,060 994 804 755 723 652
Age (median [IQR]) 81 [76, 86] 81 [78, 86] 82 [78, 87] 71 [68, 73] 66 [63, 69] 62 [59, 64] 55 [52, 59] 53 [50, 56] 80 [76, 84]
Length of stay (median [IQR]) 5 [2, 11] 4 [2, 9] 5 [2, 9] 3 [1, 6] 4 [2, 10] 3 [2, 7] 3 [1, 7] 3 [2, 7] 11 [4, 28]
30-day readmission (%) 12.3 12.1 14.7 10.3 6.6 9.6 6.6 4.7 8.3
Male (%) 50.4 40.8 41.2 52.1 63 62.8 58.7 65.6 45.2
Chronic conditions (%)
Alcohol misuse 2.3 0.2 0.2 0.3 1.7 0.6 12.5 0.6 0.8
Asthma 9.8 0.4 0.7 1.3 0.8 0.2 10.7 1 0.3
Atrial fibrillation 11.2 3.2 55.8 1.5 30.8 2.7 7.7 1.8 18.4
Cancer, lymphoma 0.1 0.3 0.1 0.1 0.2 0.1 0.7 0.4 0.8
Cancer, metastatic 4.8 0.4 0.5 0.4 1.9 5.7 3 0.1 0.5
Cancer, non-metastatic 9.3 1 1.1 1.2 1.2 1.2 4.8 0.4 0.6
Chronic kidney disease 12.3 6 61.2 6.9 9.2 20 4.2 0.3 0.2
Chronic pain 6.4 33.8 8.1 27.2 3.2 28.9 5 23.1 1.8
Chronic pulmonary disease 15.6 5.7 0.7 0.4 20.7 3.4 12.7 0.4 1.7
Cirrhosis 34.7 3.8 4 1 5.9 1.1 9.3 0.8 1.2
Dementia 1.1 0.7 0.8 4.3 1.7 1.6 12.8 2.1 0.8
Depression 2.8 0.5 0.8 2 0.2 0.6 14.8 0 0
Diabetes 13 3.6 1.1 0.5 1 0.6 0.4 0 0.9
Epilepsy 2.4 4.2 0.6 0.8 3.4 1 13 2.2 1.8
Heart failure 18.4 78.4 31.2 87.4 35.9 76.5 22.9 67.8 29.6
Hepatitis B 1 1.1 3.6 0.7 1 1.1 4.9 0.8 1.7
Hypertension 59.6 82.5 72.7 84.2 65.9 70.5 39.3 83.3 83
Hypothyroidism 5.9 0.3 1.1 0.7 1.4 0.2 8.6 0.7 1.7
Inflammatory bowel disease 0 0 0 0 0.4 0 0.5 0 0
Irritable bowel syndrome 0.2 0 0 0.1 0.4 0 0 0.1 0.2
Multiple sclerosis 0.1 0 0 0.1 0.1 0.4 0.9 0.1 0
Myocardial infarction 0.9 0.4 14.5 0.8 1.9 14.1 4.4 2.2 0.5
Parkinson’s disease 8.6 0.8 1.1 0.3 4.3 0.4 0.4 0 0.2
Peptic ulcer disease 4.9 0.4 1.1 2.6 1.3 1.7 2.5 0.3 0.6
Peripheral vascular disease 0 0 0 0.1 0.1 0.1 0 0 0
Psoriasis 0.1 0.1 0 0.5 0.3 0.4 0.7 0.7 0.3
Rheumatoid arthritis 1 3.1 0.6 0.1 1.5 0.1 9.8 0.1 0.2
Schizophrenia 0.4 1.9 0.3 4.9 0.8 0.2 7.3 0.8 0.3
Severe constipation 13.1 1 1.5 0.8 6.7 2.5 7.3 0 2.1
Stroke 4.6 2 4.4 7.5 39.3 1.4 3.8 35.4 96.8
*Bold font denotes the cluster in which the corresponding disease is most prevalent (compared with all other clusters). Underscore denotes the most prevalent three diseases within
each cluster.
with the exceptions of mental and cardiovascular patterns, other
patterns did not seem to show good evidence of universality
across populations even when stratified by statistical methods
of multimorbidity profiling (30). However, even with highly
sophisticated meta-analytic approaches, it should be noted
that across studies, different ranges of chronic conditions and
specifications of statistical analyses were adopted. Therefore,
evidence from analyses with the same methods on different
populations is important to further our understanding. This
study is one of the first attempts to narrow such a gap and as
far as we are aware, this is the first study to adopt hierarchical
agglomerative clustering analysis to compare multimorbid
patient clustering patterns.
Strengths and Limitations
Despite this novelty and the methodological strength of the well-
validated algorithms to define chronic conditions using ICD-
9 and ICD-10, this study has several limitations that require
caution in interpreting the results. First, while the Hong Kong
data are highly representative of the inpatients of the public
sector, we do not have access to patient records in the private
sector which may specialize in certain different conditions from
those found prevalent in our sample. Also, University Hospital
Zurich was our only source of Zurich data; nevertheless, it is
a well-established general acute hospital representing diverse
patient intake and standard practices. Second, the validity and
comprehensiveness of diagnostic codes may differ between sites
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TABLE 3 | Prevalence of chronic conditions by cluster (Zurich)*.
Cluster Z1 Z2 Z3 Z4 Z5 Z6 Z7 Z8 Z9
N 4,019 1,516 1,145 1,066 717 471 450 385 231
Age (median [IQR]) 80 [75, 84] 66 [61, 69] 66 [62, 70] 58 [53, 63] 73 [68, 80] 52 [49, 54] 53 [49, 57] 61 [54, 66] 56 [52, 61]
Length of stay (median [IQR]) 8 [3, 14] 5 [2, 10] 7 [3, 13] 9 [4, 15] 8 [4, 14] 7 [3, 13] 8 [4, 16] 11 [7, 17] 5 [2, 9]
30-day readmission (%) 11 11.6 15.5 16 10.6 11 9.1 7 9.5
Male (%) 51.6 71.6 67.5 50.8 36.3 70.3 50.7 67.3 88.3
Chronic conditions (%)
Alcohol misuse 2.3 14.6 2.5 12.2 2.5 11 16.4 7 3
Asthma 1.8 3.3 1.4 2.1 1.5 2.8 6.9 0.3 0.9
Atrial fibrillation 7.6 2.1 20.2 1.5 6 1.9 1.1 1.6 3
Cancer, lymphoma 1.7 0.6 1.3 7.1 1.5 1.5 2.2 0 0
Cancer, metastatic 7.7 1.6 1.6 35.6 2.8 0.6 2.2 1 0
Cancer, non-metastatic 3.6 15.8 1.7 3.5 4.9 0.4 0.4 0.3 0
Chronic kidney disease 19.1 3.4 53 2.7 10.3 25.3 3.6 4.2 18.6
Chronic pain 35.2 9.4 50.2 16.8 24.4 49.7 7.1 1.6 2.6
Chronic pulmonary disease 10.1 2.9 3.6 6.4 6.7 1.9 46.9 0.3 0.4
Cirrhosis 11.3 10.1 11.7 19.8 3.5 3 3.3 2.1 1.7
Dementia 0.1 0.8 0.3 0.8 0 1.9 1.1 0.3 0.9
Depression 0.6 3.8 0.2 6.6 0.4 2.1 1.1 0.3 0
Diabetes 8.6 0.5 1.4 0.8 3.6 0.6 0.2 0.5 0
Epilepsy 2.6 1.8 3.1 9.1 45.6 5.3 68.7 2.9 2.6
Heart failure 29.2 51.1 26.7 7.4 22.9 54.8 14.7 19 14.3
Hepatitis B 5.4 1.1 1.1 18.3 2 1.7 4 2.3 2.6
Hypertension 81.1 81.3 73.7 46.4 71.7 77.9 48.9 86.2 74.9
Hypothyroidism 4.2 1.4 3.3 17.7 59.1 2.5 8.7 5.2 1.7
Inflammatory bowel disease 0.5 0.6 0.9 1.3 0.8 0.4 1.3 1 0
Irritable bowel syndrome 0.1 0.1 0 0.3 0.3 0 1.1 0 0
Multiple sclerosis 0.2 0.4 1 0.8 0 0.2 3.1 0.3 0
Myocardial infarction 8.7 11.9 6.2 1.3 1.5 5.7 1.1 1.6 98.7
Parkinson’s disease 3.3 0.1 0.6 0.5 2 0.4 0.4 0 0.4
Peptic ulcer disease 0.4 0.8 0.4 0.8 0.8 0.2 0.2 1.6 0
Peripheral vascular disease 12.8 26.2 5 1.9 4.3 3.6 0.4 1 0.9
Psoriasis 0.4 1.4 0.5 0.5 0.7 1.5 1.1 0 0.4
Rheumatoid arthritis 4.1 2.2 1.6 8 1.7 1.5 3.8 2.6 0
Schizophrenia 0.3 0.7 0.6 4.1 1.3 1.1 0.7 0.8 0
Severe constipation 1.5 0.7 0.9 6.6 2.2 1.1 0.9 1.3 0.4
Stroke 17.1 1.8 4.3 7.6 3.6 0.6 2.2 98.7 0.4
*Bold font denotes the cluster in which the corresponding disease is most prevalent (compared with all other clusters). Underscore denotes the most prevalent three diseases within
each cluster.
and may not be sufficiently reflective of the comparison of the
true prevalence, especially considering the different healthcare
financing mechanisms (social insurance in Zurich and taxation
in Hong Kong), infrastructures, medical training, and practice
culture, which might have considerable influence on disease
coding practices (31). That might also have contributed to
the rare coding of peripheral vascular disease in Hong Kong.
Also, the codes were based on only one admission instead
of a longitudinal assessment. Nevertheless, disease diagnoses
were made by registered clinicians in each of the sites, then
complemented by ICD codes given by professional teams and can
therefore be reasonably considered a reliable source of disease
codes in the given settings of this study. Third, inpatient data
are limited to those who have already been admitted due to
acute symptoms, and therefore do not represent community
prevalence. For example, despite higher screening prevalence
of hepatitis B in Hong Kong than Zurich (32), the observed
prevalence in our Hong Kong sample is lower than that in
our Zurich sample. Therefore, the findings are not readily
generalizable to the outpatient populations in whichmultimorbid
patients requiring chronic care and medications are typically
better represented. Future studies are recommended to include
outpatient samples with well-maintained data coding consistency
and quality. Fourth, there may be under-coding of diagnoses for
which no specific screening is in place upon hospital admission
in general, such as mental disorders. Fifth, we only adopted
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FIGURE 6 | Chord diagrams showing the frequencies of disease dyads among inpatients from Cluster H9 of Hong Kong and Cluster Z8 of Zurich (stroke clusters).
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FIGURE 7 | Chord diagrams showing the frequencies of disease dyads among inpatients from Cluster H3 of Hong Kong and Cluster Z3 of Zurich (chronic kidney
disease clusters).
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a limited predetermined list of 30 diseases for the clustering
analysis. Diseases not included in the list were not used for
multimorbidity profiling. However, this approach allowed us
to use well-validated algorithms (20) that enable first insight
into the question of universality without having to validate
these algorithms for the specific settings. Importantly, the
present study provides preliminary evidence of some degree of
universality across populations. Sixth, the comparison between
the sites were mainly qualitative and no statistical tests were
applied to quantitatively summarize the differences of the
clustering patterns. However, our approach was a combination
of clinical reasoning and exploratory machine learning methods
in addressing the problem, which may facilitate future research
with similar purposes. Last but not least, as the sample were
randomly drawn from the Hong Kong and Zurich populations
only, external generalizability is limited and the analysis should
be replicated in other populations to verify the results.
To conclude, we conducted a hierarchical agglomerative
clustering analysis on discharged inpatients from Hong Kong
and Zurich based on a list of 30 diseases and provided
findings on the universality of multimorbidity patterns across
inpatient populations from the two places. Results should
be facilitative of the experimentation and development of
integrated or collaborative care for multimorbid patients in
the healthcare systems of both populations. Future research
should adopt more representative samples, longitudinal disease
coding, and comprehensive lists of chronic conditions to
verify results of this study and make recommendations
on the care planning and coordination of services for
multimorbid inpatients.
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